Exicure (XCUR) Research & Development (2016 - 2026)
Exicure's (XCUR) quarterly Research & Development came in at $312000.0 in Q1 2026, down 61.39% YoY from $808000.0 in Q1 2025, and down 52.37% on a QoQ basis from $655000.0 in Q4 2025.
Exicure (XCUR) Research & Development (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 10 years of Research & Development data on file, last reported at $312000.0 in Q1 2026.
- Quarterly Research & Development fell 61.39% year-over-year to $312000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 245.3% YoY) and the FY2025 annual result came in at $3.3 million, changed N/A from the prior year.
- Research & Development retreated to $312000.0 in Q1 2026, from $655000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $7.1 million in Q1 2022 to a low of $312000.0 in Q1 2026.
- A 4-year average of $2.5 million and a median of $1.0 million in 2022 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 30.42% in 2022, down 90.6% in 2022.
- Tracing XCUR's Research & Development over 4 years: stood at $1.1 million in 2022, then surged by 32.62% to $1.4 million in 2023, then sank by 53.97% to $655000.0 in 2025, then plunged by 52.37% to $312000.0 in 2026.
- The last three Research & Development figures came in at $312000.0 (Q1 2026), $655000.0 (Q4 2025), and $888000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Exicure | 8.41 Mn | 8.41 Mn | - | 174,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 312,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Sep 30, 2025 | 888,000.00 |
| Jun 30, 2025 | 935,000.00 |
| Mar 31, 2025 | 808,000.00 |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 4.81 Mn |
| Jun 30, 2022 | 6.75 Mn |
| Mar 31, 2022 | 7.14 Mn |
| Dec 31, 2021 | 11.42 Mn |
| Sep 30, 2021 | 16.46 Mn |
| Jun 30, 2021 | 10.84 Mn |
| Mar 31, 2021 | 10.26 Mn |
| Dec 31, 2020 | 3.75 Mn |
| Sep 30, 2020 | 9.14 Mn |
| Jun 30, 2020 | 7.01 Mn |
| Mar 31, 2020 | 6.08 Mn |
| Dec 31, 2019 | 8.27 Mn |
| Sep 30, 2019 | 4.25 Mn |